Cabenuva Medical Information - Our HIV Medications

Prescribing Information

Patient Information

Medical Information Documents
Data in Virologically Suppressed Patients

Monthly Administration

ATLAS, FLAIR, and CUSTOMIZE: Efficacy and Safety Data (MI letter)

ATLAS and FLAIR: Efficacy and Safety Data (Infographic)

Data with and without Oral Lead-In

ATLAS Week 48 Results (CROI 2019)

FLAIR Week 48 Results (CROI 2019)

ATLAS and FLAIR Week 48 Pooled Analysis (IAS 2019)

FLAIR Week 96 Results (CROI 2020)

ATLAS Week 96 Results (Glasgow 2020)

Every 2 Month Administration (ATLAS-2M)

ATLAS-2M (MI letter)

ATLAS-2M (Infographic)

Plasma Concentrations through Week 48

Week 48 Results (CROI 2020)

Week 96 Results (CROI 2021, Slides)

Week 152 Results (CROI 2022)

Treatment-Emergent Resistance Data

Overview on Occurrence of Treatment-Emergent Resistance

In vitro activity

Patient and Viral Factors on Virologic Outcome

Analysis across ATLAS, FLAIR, and ATLAS-2M (Glasgow 2020)

Data in Viremic Patients

Use in Viremic Treatment-Experienced Patients

Dosage, Administration, and Delivery

Management of Missed Injections (Monthly, MI letter)

Management of Missed Injections (Monthly, Infographic)

Management of Missed Injections (Every 2 Months, MI Letter)

Management of Missed Injections (Every 2 Months, Infographic)

Management of Underdosing (Monthly)

Management of Underdosing (Every 2 Months)

Change in Dosing Frequency

Availability of 2-inch Needles

Impact of COVID-19 on Dosing Visits (IDWeek 2020)

Use in Patients with Buttock Implants or Dermal Fillers

Implementation into Clinical Practice

CUSTOMIZE - Patient Perspectives

Considerations for Implementing (MI Letter)

Considerations for Implementing (Infographic)

Status in DHHS and IAS Guidelines

Status in DHHS and IAS Guidelines

Safety Data

Occurrence of Injection Site Reactions (MI letter)

Occurrence of Injection Site Reactions (Infographic)

Post-Injection Reactions

Effects on Bone

Effects on Weight (MI Letter)

Drug Interactions

Use with COVID-19 Vaccines and Therapeutics

Use with Tecovirimat

Data in Pediatrics

Use in Pediatric Patients

Special Populations

Use in Pregnancy

Use in Patients with Renal or Hepatic Impairment

Patient Reported Outcomes

Monthly Administration (MI letter)

Monthly Administration (Infographic)

Every 2 Month Administration

Storage and Stability

Storage Conditions
On Demand Medical Videos
Congress Data

Discussing CABENUVA Data at AIDS 2022

Bruce Gilliam, MD, FACP Sr. Medical Director, North American Medical Affairs
Dr. Moti Ramgopal, MD, FIDSA, FACP Associate Professor of Medicine Medical Director Midway Reasearch Center and Found of Midway Specialty Care Centers

Discussing CABENUVA Data at AIDS 2022
Bruce Gilliam, MD, FACP Sr. Medical Director, North American Medical Affairs
Dr. Moti Ramgopal, MD, FIDSA, FACP Associate Professor of Medicine Medical Director Midway Reasearch Center and Found of Midway Specialty Care Centers

Cabenuva Post CROI 2022 Discussion

Andrew Zolopa, MD—Head North American Medical Affairs, ViiV Healthcare
Paula Teichner, PharmD—Regional Medical Lead, Cabotegravir, ViiV Healthcare
Mark Lewandowski, PharmD —Medical Director, ViiV Healthcare

Cabenuva Post CROI 2022 Discussion
Andrew Zolopa, MD—Head North American Medical Affairs, ViiV Healthcare
Paula Teichner, PharmD—Regional Medical Lead, Cabotegravir, ViiV Healthcare
Mark Lewandowski, PharmD —Medical Director, ViiV Healthcare

ATLAS 2M Week 152 Data - Discussion and Application to Clinical Practice

Paula Teichner, PharmD—Regional Medical Lead, Cabotegravir
Jean Van Wyk, MBChB; MFPM—VP and Global Medical Lead, Cabotegravir

ATLAS 2M Week 152 Data - Discussion and Application to Clinical Practice
Paula Teichner, PharmD—Regional Medical Lead, Cabotegravir
Jean Van Wyk, MBChB; MFPM—VP and Global Medical Lead, Cabotegravir

Post-CROI 2021 Webinar

Andrew Zolopa, MD, VP, Head, North America Medical Affairs

Post-CROI 2021 Webinar
Andrew Zolopa, MD, VP, Head, North America Medical Affairs

Clinical Trials Data

Cabenuva Post CROI 2022 Discussion

Andrew Zolopa, MD—Head North American Medical Affairs, ViiV Healthcare
Paula Teichner, PharmD—Regional Medical Lead, Cabotegravir, ViiV Healthcare
Mark Lewandowski, PharmD —Medical Director, ViiV Healthcare

Cabenuva Post CROI 2022 Discussion
Andrew Zolopa, MD—Head North American Medical Affairs, ViiV Healthcare
Paula Teichner, PharmD—Regional Medical Lead, Cabotegravir, ViiV Healthcare
Mark Lewandowski, PharmD —Medical Director, ViiV Healthcare

ATLAS 2M Week 152 Data - Discussion and Application to Clinical Practice

Paula Teichner, PharmD—Regional Medical Lead, Cabotegravir
Jean Van Wyk, MBChB; MFPM—VP and Global Medical Lead, Cabotegravir

ATLAS 2M Week 152 Data - Discussion and Application to Clinical Practice
Paula Teichner, PharmD—Regional Medical Lead, Cabotegravir
Jean Van Wyk, MBChB; MFPM—VP and Global Medical Lead, Cabotegravir

The ABCs of CAB: Incorporating Long-Acting Cabenuva into Clinical Practice

Paula Teichner, PharmD, AAHIVP, Regional Medical Lead

The ABCs of CAB: Incorporating Long-Acting Cabenuva into Clinical Practice
Paula Teichner, PharmD, AAHIVP, Regional Medical Lead

Post-CROI 2021 Webinar

Andrew Zolopa, MD, VP, Head, North America Medical Affairs

Post-CROI 2021 Webinar
Andrew Zolopa, MD, VP, Head, North America Medical Affairs

Data in Virologically Suppressed Patients

Every 2 Month Administration (ATLAS-2M)

Week 96 Results (CROI 2021, Video)

Week 96 Results (CROI 2021, Video)

Week 152 Results – Discussion and Application to Clinical Practice (Video)

Week 152 Results – Discussion and Application to Clinical Practice (Video)

Safety Data

Weight and Lipid Changes (CROI 2021)

Weight and Lipid Changes (CROI 2021)
Implementation Resources

ViiV resources on considerations to implement Cabenuva into clinical practice:

CABENUVA Implementation Guidance for Clinics

Considerations to Implement CABENUVA

The ABCs of CAB: Incorporating Long-Acting CABENUVA Into Clinical Practice

For information on select publicly available resources to help providers implement CABENUVA into clinical practice, visit the following:

AAHIVM Long-Acting Agents Resource Center (hivlaa.org)

HIVMA: Cabenuva Considerations for Health Care Providers
long-acting-antiretroviral-treatment-considerations-for-health-care-providers.pdf (hivma.org)

NYSDOH AIDS Institute Guideline: Use of Injectable CAB/RPV LA as Replacement ART in Virally Suppressed Adults
Use of Injectable CAB/RPV LA as Replacement ART in Virally Suppressed Adults - AIDS Institute Clinical Guidelines (hivguidelines.org)

Connect With Us

Are you a US healthcare provider?

This web portal is intended as an educational resource for healthcare providers practicing in the United States. It may include information about products or uses that have not been approved by the US Food and Drug Administration.

If you are not a healthcare provider, please discuss any questions you have regarding your health or medicines with your doctor, pharmacist, or nurse.

Yes